The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study - Concepedia

Concepedia

Publication | Closed Access

The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study

69

Citations

43

References

2004

Year

Triantafyllos Didangelos, Anastasia Thanopoulou, Stavros Bousboulas, Christos Sambanis, Vasilios G. Athyros, Elefteria Spanou, Kostantina Dimitriou, Stavros Pappas, B. Karamanos, Dimitrios T. Karamitsos

Current Medical Research and Opinion

Abstract

Orlistat plus HCD favourably modified several cardiovascular risk factors in patients with both MetSyn and type 2 DM. These effects might partly offset the excess cardiovascular risk and improve outcome in this patient population.

References

	Year	Citations

Page 1